CanPath is working in partnership to prevent disease and provide a platform for scientists to conduct innovative research.
The Canadian Partnership Against Cancer established the Canadian Partnership for Tomorrow Project (now CanPath) in June 2008.
Meet the members of CanPath's Leadership Team, Operations Committee, National Strategic Advisory Council and more.
Meet the members of CanPath's operational core, based at the University of Toronto's Dalla Lana School of Public Health.
Seven regional cohorts across ten provinces comprise CanPath's pan-Canadian partnership.
Learn more about the partner organizations that provide funding and in-kind support to CanPath.
Find out how CanPath will improve the health of Canadians and more.
How to reach CanPath by phone, email, in-person, or make a data access request.
CanPath is Canada’s largest population health cohort and a gateway platform to data worldwide.
The CanPath Access Portal provides researchers with the necessary resources to identify epidemiological and biological data available from participating cohorts to answer innovative research questions.
CanPath has supported more than 100 research projects and activities, many of which have resulted in publications in high impact journals.
These publications are examples of research made possible with data from CanPath and its regional cohorts.
As Canada’s largest population health study, CanPath responded quickly to the pandemic by leveraging its existing infrastructure to support national COVID-19 research.
CanPath's Student Dataset provides students the unique opportunity to gain hands-on experience working with CanPath data.
The CanPath team is committed to collaborating with partners in order to enhance and accelerate research for a healthier Canada.
Understand the unique social, economic and health characteristics of CanPath participants and how this information is captured for research.
Hundreds of thousands of Canadians have come together to be part of a study that reveals real breakthroughs.
CanPath and its regional cohorts are conducting a COVID-19 antibody study of 20,000 participants across Canada.
Find out what’s new at CanPath, register for an upcoming webinar, and more.
Over 50% of patients with diabetes develop complications, including cardiovascular diseases, kidney disease, and eye conditions. For Dr. Ye, these concerns motivated his urgency to […]